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Abstract 
Crohn's disease is a relapsing-remitting disorder of the 
gastrointestinal tract caused by a mixture of genetic and en-
vironmental factors. Pharmacologic treatment of Crohn's 
disease is patient-specific, and regimens vary widely be-
tween individuals. Drug regimens are typically based on 
5-aminosalicylate therapy and may include a combination of 
steroids, histamine 2 receptor antagonists, proton pump in-
hibitors, immunomodulators, antibiotics, biologic agents and 
other medications aimed at symptom relief. A new medica-
tion, vedolizumab, is currently in phase III clinical trials 
awaiting U.S. Food and Drug Administration (FDA) approval 
for use in Crohn's disease. Vedolizumab is an alpha-integrin 
inhibitor, which is anticipated to have a better safety profile 
than Tysabri® ( natalizumab ), an alpha-integrin inhibitor 
already approved for treatment of Crohn's disease. Pharma-
cists have an opportunity to educate Crohn's disease patients 
about nonpharmacologic management including counseling 
on diet, exercise, stress-relief therapy and use of multivita-
mins as well as the importance of regular colonoscopies and 
visits to a primary care practitioner. Pharmacists can also 
educate patients and practitioners about alternative thera-
pies including probiotics, fecal microbiota transplantation 
and fish oils which may help manage the disease. 
Introduction 
Crohn's disease is an inflammatory bowel disease (IBD), 
which can negatively affect the lives of many patients. While 
there are both pharmacologic and nonpharmacologic steps 
all patients can take to suppress the disease and its complica-
tions, treatment is highly individualized. Many patients will 
often not respond to initial therapy or may lose responsive-
ness over time. The need for new medications to combat 
Crohn's disease is highly recognized. Vedolizumab has com-
pleted phase III clinical trials and is awaiting FDA approval. 
Its safety and efficacy in these trials are encouraging for po-
tential use in Crohn's disease patients. Pharmacists can play 
a large role in the management of these patients, as they will 
be instrumental in monitoring complex drug therapies, en-
suring appropriate laboratory testing, and educating patients 
on diet, other nonpharmacologic treatments, and new inves-
tigational therapies. Pharmacists have the opportunity to 
make a difference in improving the quality of life of Crohn's 
disease patients in multiple settings, which include commu-
nity, institutional, specialty pharmacy and primary care prac-
tice. 
Background of Disease and Traditional Therapy 
Crohn's disease is an increasingly prevalent idiopathic form 
of IBD. Since it affects all ages and ethnicities, as well as both 
men and women, Crohn's disease plays a significant role in 
the lives of approximately 6 million Americans.1 The chronic, 
relapsing autoimmune inflammatory nature of this disease 
typically presents as a discontinuation of the mucosa of the 
gastrointestinal tract (GIT) and may result in complications 
such as strictures, fistulas, lesions, obstructions or abscesses. 
Lesions of the intestine are oftentimes irreversible. While the 
mucosa of the entire GIT from the mouth to the anus can be 
affected, the majority of cases are located in the terminal il-
eum and colon. Clinical implications include diarrhea or con-
stipation, fever, abdominal pain, passage of mucus and blood 
in the stool, signs of bowel obstruction, mouth sores and 
clubbing of the fingernails,2,3 Diarrhea, as demonstrated by 
an increase in frequency and decrease in consistency of stool, 
is the most common clinical implication. Abdominal pain, 
another common symptom, is typically seen in the right 
lower quadrant and is exacerbated by eating.3 As a result of 
this exacerbation with food, weight loss is a frequent occur-
rence in Crohn's disease.4 
Crohn's disease is not a reportable condition in the United 
States, which limits the ability to determine which popula-
tions are at highest risk. Data is also skewed by the difficulty 
in differentiating Crohn's disease from a similar form of IBD 
known as ulcerative colitis. Researchers have conducted mul-
tiple studies to determine the populations that have the high-
est incidence of Crohn's disease. Crohn's disease may occur 
at any age, but most cases are diagnosed in early adulthood 
with a large peak in adults 20 to 30 years old. A second peak 
of incidence occurs in adults 50 to 60 years old.1.s About 25 
percent of IBO diagnoses occur during childhood and, unfor-
tunately, pediatric patients generally present with a more 
severe form.s Pediatric cases of Crohn's disease occur more 
often in boys than girls, but in adults more cases occur in 
women than men. Data indicate more cases of Crohn's dis-
ease in the Northeast and Midwest regions of the United 
States when compared to the Southern and Western re-
gions.1 Historically, Crohn's disease is most common in Cau-
casians, with a genetic-based increase in prevalence among 
individuals of Eastern European (Ashkenazi) Jewish de-
scent.6 However, recent studies have shown an increase in 
the rate of African-Americans presenting with Crohn's dis-
ease, and the rate of Crohn's-induced hospitalizations of Afri-
can-Americans is now similar to Caucasians. Incidence in 
Asian-Americans and Hispanic-Americans is significantly 
lower compared to Caucasians and African-Americans.7 
The exact cause of Crohn's disease is unknown, but the dis-
ease seems to be influenced by both genetics and environ-
mental factors. Genome-wide association studies have shown 
genetic variance to be the major contributor to about 23 per-
cent of cases. These genetic variants have been shown to al-
ter the regulation and efficiency of key molecular pathways 
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Five classes of drugs affecting the small and large intestine 
are typically utilized for Crohn's disease: 5-aminosalicylates, 
immunomodulators, antibiotics, corticosteroids and biolog-
ics. For mild to moderate disease, 5-aminosalicylates such as 
mesalamine, sulfasalazine, olsalazine and balsalazide are 
most commonly used as first-line therapy to achieve remis-
sion. Topical mesalamine in the form of suppositories or ene-
mas can be effective in treating distal Crohn's disease and 
maintaining remission in mild to moderate patients. Immu-
nomodulators such as azathioprine, mercaptopurine (6-MP), 
and methotrexate (MTX) are useful in maintaining remission 
when 5-aminosalicylates fail, in steroid-dependent disease 
and in fistulizing disease. The use of the immunomodulator 
cyclosporine is limited to cases of severe disease in which 
other treatments have failed, due to its risk of serious side 
effects. It is typically administered intravenously as a last 
ditch effort to a hospitalized patient in an effort to prevent or 
delay surgery. Antibiotics, including ciprofloxacin and met-
ronidazole, can be used to treat fistulizing disease and flare-
ups, while also playing a role in achieving remission in mild 
to moderate disease when 5-aminosalicylates are not suffi-
cient. Corticosteroids such as prednisone can be used to treat 
acute flares and to induce remission in moderate to severe 
disease, but should never be used long-term to maintain re-
mission since it has a high incidence of serious side effects 
including infection, osteoporosis, adrenal insufficiency, glau-
coma, muscle wasting, fat redistribution and hypertension. 
Corticosteroids should be tapered down slowly and as early 
as possible in order to avoid these serious complications. 
Biologics are typically reserved for fistulizing disease or se-
vere disease refractory to other medication classes. Biologics 
are commonly used as an alternative to immunomodulators 
or occasionally in combination with immunomodulators, 
although combination of these two classes is highly de-
bated.11 Biologics include tumor necrosis factor alpha (TNF-
a) inhibitors adalimumab, infliximab, and certolizumab pe-
gol, as well as the alpha-4 integrin inhibitor, natalizumab. 
in the body such as microbial defense, innate immune re-
sponses, autophagy, reactive oxygen species generation, and 
lymphocyte differentiation.s Due to altered regulation, the 
GIT is more prone to chronic injury and infection. Although 
microorganisms such as Escherichia coli, Salmonella spp. and 
Campylobacter spp. have been hypothesized to trigger the 
onset of Crohn's disease, researchers have not been able to 
pinpoint one specific microorganism as the causative agent.9 
These harmful microorganisms can adhere to epithelial cells 
of the intestine, replicate and stimulate an immune response, 
which induces epithelial cell injury, causing inflammation 
and discontinuation of the intestinal mucosa. Crohn's disease 
patients are also commonly postulated to have a "leaky gut" 
in which intestinal permeability is increased, resulting in 
intestinal substances leaking out into the bloodstream. More-
over, most Crohn's disease patients have altered bowel flora, 
which leaves the GIT unable to defend against the activity of 
harmful microorganisms.3,s 
Many factors contribute to an increase in harmful microor-
ganisms in the intestinal mucosa. For example, the consump-
tion of refined sugars and preservatives present in many 
foods in the United States and other industrialized areas fa-
vor growth of detrimental bacteria in the intestine. As a re-
sult, diet can be a key component in the management of 
Crohn's disease. Children growing up in areas with poor sani-
tation are exposed to an increased repertoire of pathogens 
and infections, and thus, develop a more robust immune sys-
tem. Therefore, these children may be protected against 
agents which may induce Crohn's disease, resulting in lower 
prevalence in children in areas of poor hygiene compared to 
children who grow up with increased sanitation and less 
pathogen exposure in industrialized areas. This idea is 
known as the hygiene hypothesis and is theorized as a con-
tributor to the development of IBD.10 Drug-induced Crohn's 
disease is also possible. Chronic use of antibiotics can kill 
protective bacteria in the intestine leaving the epithelial cells 
more prone to injury by harmful microorganisms. Other risk 
factors for developing Crohn's disease include cigarette 
smoking and use of oral contraceptives.7 
Currently, no definitive diagnostic test exists for Crohn's dis-
ease. Analysis of symptoms and clinical laboratory values as 
well as endoscopic, histologic, and radiologic examination 
criteria lead to confirmation of the disease.2,4 There is no gold 
standard when it comes to treating Crohn's disease. There 
are several different treatment guidelines available, includ-
ing those from the American Academy of Family Physicians 
(AAFP), the American College of Gastroenterology (ACG), and 
the American Gastroenterological Association (AGA). How-
ever, the guidelines do not agree on a strong first-line 
recommendation. Therefore, optimal first-line therapy is pa-
tient-specific and dependent on the location, severity and 
any complications of the disease that are present. The two 
primary goals of therapy are to treat acute flare-ups of symp-
toms and maintain remission. Other goals of therapy are lim-
iting exposure to corticosteroids, minimizing adverse effects 
of therapy, decreasing hospitalizations and improving pa-
tients' quality of life. 
New Drug Therapy: Vedolizumab 
Patients with moderate to severe Crohn's disease have often 
tried and failed many medications including TNF-a inhibitors 
such as adalimumab, infliximab and certolizumab pegol. 
There is an unmet need for new therapies to treat patients 
with severe disease. A new class of medications, known as 
alpha-4 integrin inhibitors, has been developed for this pur-
pose. This class includes the medication natalizumab 
(Tysabri®), which is FDA approved for Crohn's disease. In-
tegrin inhibitors act to prevent leukocyte extravasation 
(crossing the endothelium of blood vessels) into the mucosa 
of the GIT, which decreases the inflammatory response in 
patients who have an upregulated, dysfunctional immune 
system.12 Extravasation of leukocytes involves the coordi-
nated efforts of leukocytes and vascular endothelial cells. 
lntegrins on the surfaces of leukocytes bind to receptors on 
endothelial cells and activate intracellular signaling. The ex-
travasation process involves multiple steps including tether-
ing, rolling, activation, adhesion, extravasation and migration 
as the leukocytes enter the GIT.12,n In Crohn's disease, it is 
the T-cells expressing a4j37 integrin, which exclusively bind 
to endothelium in the GIT and lymphoid tissue.12 The a4j37 
July 2014 Volume 5, Issue 3 THE PHARMACY AND WELLNESS REVIEW 23 
Gastroen terology Crohn's Disease: Management, Emerging Therapies and the Role of the Pharmacist 
integrin binds to mucosa! addressin-cell adhesion molecule-1 
(MAdCAM-1), which is a receptor only expressed on the vas-
culature of the GIT.12.14 MAdCAM-1 increases T-cell deposi-
tion in the GIT and is a major contributor to inflammation in 
this region. Natalizumab was developed as a monoclonal an-
tibody, which binds to the a4 integrin monomer, resulting in 
binding both a4 integrin heterodimers on T cells, a4~7 and 
a4~1, to block their respective attachments to the vascular 
cell adhesion molecule-1 (VCAM-1) and MAdCAM-1. Binding 
to a4~7 and a4~1 prevents integrin association with the 
endothelial receptors and reduces extravasation of inflam-
matory cells. Natalizumab has been used successfully for 
treatment in Crohn's disease, ulcerative colitis and multiple 
sclerosis.12 While it has displayed efficacy in multiple dis-
eases, natalizumab has a major drawback of causing a seri-
ous and often fatal disease known as progressive multifocal 
leukoencephalopathy (PML) caused by the John Cunningham 
(JC) virus.12 Natalizumab was withdrawn from the market by 
the FDA and reintroduced in 2006 with a specialized Risk 
Evaluation and Mitigation Strategy (REMS) safety prescrib-
ing program.12 The reason for this effect with natalizumab is 
prevention of a4~1 integrin from binding to VCAM-1, which 
is thought to negatively affect immunity in the central nerv-
ous system and increase the risk for development of PML. 
Vedolizumab, a humanized version of a mouse antibody, se-
lectively binds the a4~7 integrin.12,13 Vedolizumab is a 
smaller molecule than natalizumab allowing it to selectively 
target GIT integrins. Also, vedolizumab does not affect bind-
ing to VCAM-1 and has not yet been associated with develop-
ment of PML.12,14 Like natalizumab, vedolizumab is adminis-
tered intravenously. Vedolizumab has completed phase Ill 
clinical trials and is awaiting FDA approval to be brought to 
market.12 
A phase lII randomized, parallel-group, placebo-controlled, 
double-blinded study conducted from December 2008 to 
May 2012 evaluated the safety and efficacy of vedolizumab 
as induction and maintenance therapy for Crohn's disease. 
Inclusion criteria included patients 18 to 80 years old with at 
least a three month history of Crohn's disease with a Crohn's 
Disease Activity Index (CDAI) of 220 to 450 (CDAI scores 
range from 0 to 600 with higher scores pointing to greater 
disease activity). Patients also had to have other gastrointes-
tinal markers of certain severity including: C-reactive pro-
tein, colonoscopy findings or fecal calprotectin. Patients had 
to be unresponsive or previously display unacceptable side 
effects with glucocorticoid therapy, immunosuppressive 
agents, or TNF-a inhibitors. Exclusion criteria encompass 
patients with severe disease complications such as stoma, 
extensive small-bowel or colon resections, strictures, ab-
dominal abscesses, cancer and tuberculosis. Patients were 
screened using physical exams, neurologic exams and ques-
tionnaires, including one to classify symptoms of PML as well 
as the Inflammatory Bowel Disease Questionnaire.is 
The trial investigated both induction and maintenance treat-
ment using vedolizumab. For the induction component, pa-
tients were randomized to receive placebo or vedolizumab 
300 mg at weeks 0 and 2 and were assessed for disease 
status through week 6. A second open-label cohort received 
the same regimen of vedolizumab as the previously 
mentioned group receiving induction therapy. This group of 
patients was included in the study to meet sample size re-
quirements for the maintenance phase of the trial. Patients 
eligible for the maintenance phase of the study were patients 
from both cohorts who displayed a clinical response to ve-
dolizumab at week 6. Participants were randomized in a 
1:1:1 fashion to vedolizumab dosed every four weeks, every 
eight weeks or placebo (frequency not specified) for 
52 weeks. Patients who did not achieve a clinical response to 
vedolizumab by week 6 of induction therapy continued to 
receive vedolizumab 300 mg every four weeks for 52 weeks. 
Patients in the placebo group during the induction phase 
remained in the placebo group for the maintenance phase.is 
Primary end points for the induction trial were clinical re-
mission defined by a CDAI less than or equal to 150 and a 
CDAI-100 response, defined as a 100 point CDAI score reduc-
tion. The secondary end point was the change in C-reactive 
protein from baseline to 6 weeks. Statistical significance for 
the entire trial was set at 5 percent (alpha=0.05). Results 
showed 14.5 percent of patients receiving vedolizumab and 
6.8 percent of patients receiving placebo reached clinical 
remission by week 6 (p=0.02). Of those receiving vedolizu-
mab and placebo, 31.4 percent and 25.7 percent, respec-
tively, had a CDAI-100 response (p=0.23). Changes in 
C-reactive protein were similar across both groups.JS 
The primary end point for the maintenance trial was clinical 
remission at week 52 and the secondary end points were 
CDAI-100 response at week 52, remission at week 52 with-
out the use of glucocorticoids, and clinical remission at 
greater than or equal to 80 percent of all study visits includ-
ing the final visit at week 52. Results showed 36.4 percent of 
patients receiving vedolizumab every four weeks and 39 per-
cent of patients receiving vedolizumab every eight weeks 
were in clinical remission at week 52. Only 21.6 percent of 
patients in the placebo group reached clinical remission, pro-
ducing comparison p-values of p=0.004 and p<0.001 for the 
four-week and eight-week vedolizumab groups compared to 
placebo, respectively. Vedolizumab groups also showed a 
trend towards greater proportions of patients with a CDAI-
100 response and glucocorticoid-free remission than with 
placebo; however, the differences in clinical remission were 
not significant.ls 
This trial displayed moderate effects on induction and main-
tenance of clinical remission in patients with moderate to 
severe Crohn's disease who received vedolizumab therapy. 
Patients enrolled in the study had refractory disease and ap-
proximately 50 percent of patients had prior treatment fail-
ure to other medications, including TNF-a inhibitors. Further 
trials are necessary to determine which patients may benefit 
most from vedolizumab therapy. Once it comes to market, 
vedolizumab will likely be a safer choice than natalizumab 
for Crohn's disease due to a lower incidence of PML.lS 
On Dec. 9, 2013, a joint meeting of the FDA's Gastrointestinal 
Drugs Advisory Committee and the Drug Safety and Risk 
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providing symptomatic relief and preventing exacerbations. 
Options for stress relief include relaxation, breathing exer-
cises, meditation, acupuncture, reading books and other re-
laxing activities.20 Implementing low-intensity exercise for 
30 minutes three times per week aids in diminishing depres-
sion, which often accompanies Crohn's disease.21 
Management Advisory Committee recommended vedolizu-
mab for use in Crohn's disease as well as ulcerative colitis. 
Specific recommendations for vedolizumab therapy in 
Crohn's disease included use in patients who failed TNF-a 
inhibitors or conventional therapy to reduce signs and 
symptoms, to achieve clinical remission or glucocorticoid-
free remission and to stimulate mucosa! healing in moderate 
to severe Crohn's disease. The committee reached unani-
mous agreement that Takeda Pharmaceuticals appropriately 
characterized the low risk of PML with vedolizumab therapy 
to support approval.16 Although the committee has shown 
support, vedolizumab still needs FDA approval. The FDA has 
set a Prescription Drug User Fee Act (PDUFA) Priority Re-
view action date for the indication ofvedolizumab in ulcera-
tive colitis as May 20, 2014. This date is a target for the FDA 
to make a final decision on approval. A PDUF A standard re-
view action date for indication in Crohn's disease has been 
made for June 18, 2014.17 If approved, vedolizumab will en-
ter the market under the brand name Entyvio®. 
Nonpharmacologic Treatment 
Along with standard pharmacologic treatments, nonpharma-
cologic treatments have proven beneficial for Crohn's disease 
patients. Lifestyle modifications such as dietary changes and 
symptomatic or supportive treatment are important. Main-
taining a well-balanced diet promotes healing and relieves 
symptoms in many patients suffering from Crohn's disease. 
Good nutrition helps compensate for nutritional losses due 
to Crohn's disease. Dietary suggestions are different depend-
ing on whether the patient is in a period of active or inactive 
disease. When the disease state is inactive, patients should 
stay hydrated and consume low fiber carbohydrates like leg-
umes, oat bran, and barley, proteins such as lean meats and 
eggs, healthy fats like olive oil, fruits, and vegetables. When a 
patient's disease is active, health care professionals can rec-
ommend applesauce, bananas, bland foods, soft foods, plain 
cereals, proteins as accepted, and small, frequent meals. 18 
Patients with active disease should also be educated to avoid 
high fiber foods, high fat foods, nuts, seeds, popcorn, gluten, 
caffeine, alcohol, raw fruits, raw vegetables, dairy, spicy 
foods, and larger portions. However, all dietary recommen-
dations remain patient specific. Each patient may also pos-
sess his or her own specific trigger food, which should be 
avoided, because it may cause flares of symptoms and de-
creased quality of life. Patients should be advised to keep a 
food diary, which should include all foods eaten each day as 
well as Crohn's disease symptoms such as abdominal pain, a 
description of bowel habits and overall well-being. This 
process helps identify triggers, encourages patients to eat 
well-balanced foods and allows positive dietary habits to be 
observed. Overall, Crohn's disease manifests differently be-
tween individuals; therefore, it is best to individualize each 
patient's diet to alleviate symptoms. 
Maintaining a healthy diet is important, but there are other 
nonpharmacologic therapies that may help reduce flare-ups 
and prevent symptoms. First, those suffering with Crohn's 
disease should stop smoking as this worsens symptoms and 
can decrease responsiveness to certain treatments.19 Also, 
stress relief and general health maintenance are beneficial in 
Numerous other complementary alternative medicines are 
available. These are believed to be safe, but may require ad-
ditional studies to elucidate efficacy in the treatment of 
Crohn's disease. These options include probiotics, fecal mi-
crobiota transplantation and fish oils. Probiotics are living 
microbial food ingredients, which beneficially alter the intes-
tinal flora in an unknown mechanism. Although studies re-
garding probiotics in Crohn's disease have resulted in mixed 
conclusions on efficacy, the use of VSL#3 specifically may 
help patients achieve remission. VSL#3 is a mixture of eight 
different strands of bacteria, which influence the immune 
response by several mechanisms.23 Fecal microbiota trans-
plantation represents an alternative therapy to use when 
standard treatments have failed. This process involves trans-
ferring a safe, donated stool into the patient via an enema or 
nasogastric tube in order to replenish and balance bacteria in 
the colon.z4 Fish oils and omega-3 fatty acids may have posi-
tive anti-inflammatory effects in the intestines.22 Even though 
all of these options are still under investigation, they may be 
good options for the treatment of Crohn's disease. 
After medications and nonpharmacologic treatments fail as 
treatment for Crohn's disease, surgery is the final option. 
According to the National Cooperative Crohn's Disease Study, 
the probability of requiring surgery is 78 percent after 
20 years of Crohn's disease symptoms, and the probability 
jumps to 90 percent after 30 years of symptoms.zs Possible 
procedures include strictureplasty, resection, colectomy, re-
moval of abscesses (pus-filled sacs) and correction of abnor-
mal tracts or fistulas.26 However, surgery is not curative and 
is a last-ditch effort for treating Crohn's disease. 
The Pharmacist's Role 
As health care providers, pharmacists must be educated in 
Crohn's disease pharmacologic and nonpharmacologic 
treatments as well as appropriate patient counseling and 
recommendation points. Pharmacists should highlight the 
importance of avoiding non-steroidal anti-inflammatory 
drugs (NSAIDs) such as ibuprofen and naproxen due to 
bleeding risk. Within one week of therapy with NSAIDs, ap-
proximately 25 percent of patients have flares.19 Many 
Crohn's disease patients experience deficiencies in folate and 
vitamin 812. Vitamin 812 deficiency is especially prevalent 
when the ileum is affected since this is the primary site of 
absorption of vitamin 812. Therefore, pharmacists should 
recommend frequent screenings and supplementation. Since 
sulfasalazine and methotrexate impair folate metabolism, 
patients taking these medications require more folic acid 
than patients not on these therapies.27 Vitamin D and calcium 
may also be depleted in Crohn's disease patients due to 
impaired absorption putting patients at increased risk for 
osteoporosis.zs Vitamins and supplements should be taken 
during both the active and inactive phases of the disease to 
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replenish deficiencies.22 Another counseling point to empha-
size is the necessity for periodic colonoscopies in which the 
frequency is determined by disease severity, duration and 
personal or family history of colorectal cancer. The risk of 
acquiring colorectal cancer significantly increases eight to 10 
years after development of Crohn's disease, and at that point, 
patients may require regular colonoscopies every one to two 
years.29 It is important to ensure that patients keep a list of 
any supplements, over-the-counter or prescription medica-
tions they take in order to keep their doctors, pharmacists 
and other health care professionals informed. Pharmacists 
should also counsel patients on nonpharmacologic treat-
ments, including foods and drinks to avoid and those that 
may be better options. As the most accessible health care 
provider, it is important for pharmacists to remain knowl-
edgeable and up-to-date on new treatments, recommenda-
tions and counseling points to benefit patients suffering from 
Crohn's disease. 
Conclusion 
Crohn's disease patients may feel overwhelmed or burdened 
by their disease state and the complexity of their medication 
regimens. When experiencing a disease flare, the quality of 
life of a Crohn's disease patient is negatively affected. Phar-
macists play a large role in helping these patients to better 
manage their medications and can provide great insight into 
the various pharmacologic and nonpharmacologic therapies 
available for treatment of Crohn's disease. 
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